Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia
| Status: | Completed |
|---|---|
| Conditions: | Anemia |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | Any - 60 |
| Updated: | 3/25/2017 |
| Start Date: | February 2007 |
| End Date: | August 16, 2016 |
Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia, Using Matched Unrelated Donors and Mismatched Related Donors
For patients with severe aplastic anemia (SAA) who have failed to respond to
immunosuppressive therapy and lack an HLA identical family member, our objectives are to
make an initial assessment of the safety and efficacy of allogenic stem cell transplantation
from either a matched unrelated donor or a mismatched reacted donor using the conditioning
regimen of Cytoxan, reduced total body irradiation (TBI) and Campath IH. The principle
measures of safety and efficacy will be :
1. Patient survival probability at 100 days, 1 year and 2 years.
2. Incidence of graft versus host disease (GVHD), as well as incidence of acute GVHD and
chronic GVHD within 6 months and 2 years.
3. Engraftment at 6 months, 1 year and 2 years
immunosuppressive therapy and lack an HLA identical family member, our objectives are to
make an initial assessment of the safety and efficacy of allogenic stem cell transplantation
from either a matched unrelated donor or a mismatched reacted donor using the conditioning
regimen of Cytoxan, reduced total body irradiation (TBI) and Campath IH. The principle
measures of safety and efficacy will be :
1. Patient survival probability at 100 days, 1 year and 2 years.
2. Incidence of graft versus host disease (GVHD), as well as incidence of acute GVHD and
chronic GVHD within 6 months and 2 years.
3. Engraftment at 6 months, 1 year and 2 years
The objective of this trial is to make an initial assessment for this new treatment regimen
and to show it is equal or superior to the current standard practice. With this initial
assessment be hope to gain information suggesting further study of this regimen or
discontinuation of this regimen before exposing large numbers of patients to this new
treatment option. We also will gain experience with this new regimen giving insights as to
possible modifications in dosing and monitoring and selection of patients for future
treatment in case of positive results. For this initial study we plan to enroll up to 24
patients.
and to show it is equal or superior to the current standard practice. With this initial
assessment be hope to gain information suggesting further study of this regimen or
discontinuation of this regimen before exposing large numbers of patients to this new
treatment option. We also will gain experience with this new regimen giving insights as to
possible modifications in dosing and monitoring and selection of patients for future
treatment in case of positive results. For this initial study we plan to enroll up to 24
patients.
Inclusion Criteria:
- Diagnosis of SAA based on bone marrow aspirate and biopsy results. Failure to respond
to immunosuppressive therapy and/or lack of an HLA identical family member.
- A 10/10 or 9/10 HLA matched unrelated donor or a 9/10 matched related donor available
after high resolution typing.
Exclusion Criteria:
- Patients with Aplastic anemia and active infection must be treated to maximally
resolve this problem before beginning the conditioning regimen.
- HIV seropositive patients
- Patients who have clonal cytogenetic abnormalities or a myelodysplastic syndrome.
- Patient greater than 60 years of age.
- Women who are pregnant or nursing.
- Patients with active hepatitis
- Patients with severe cardiac dysfunction defined as shortening fraction <25%.
- Patients with severe renal dysfunction defined as creatinine clearance
<40ml/mim/1.73m2.
- Patient with severe pulmonary dysfunction with FEV1, FVC and DLCO 40% of predicted or
3 SD below normal.
We found this trial at
1
site
Rochester, Minnesota 55905
Principal Investigator: Shakila P Khan, M.D
Phone: 507-284-3442
Click here to add this to my saved trials
